Could the CEO of Valeant Pharmaceuticals Intl Inc. Be the Next Warren Buffett?

Warren Buffett has grown his empire by buying great companies. The CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing the exact same thing. Could that make him the next Buffett?

| More on:
The Motley Fool

One thing that Warren Buffett does very well is buy businesses. With the amount of capital that he has available to him through Berkshire Hathaway Inc., he can go out and buy out an entire company without blinking an eye.

And then when he does buy these companies, he is able to integrate them into the overall structure, and take the cash flow they provide to make even larger investments. This is how Buffett went from buying stocks—which he still does to an extent—to outright buying businesses.

Believe it or not, J. Michael Pearson, the CEO of Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) is doing something quite similar. And Bill Ackman, the hedge fund manager of Pershing Square Capital, believes that Valeant could be this generation’s Berkshire.

Ackman has invested 20% of his funds into Valeant. The reason he believes that he is holding a large stake in the next Berkshire is because of how many acquisitions Valeant makes every year. He views the company as a “platform company,” meaning it buys other companies to increase its own value. Instead of launching organic projects, it just buys them. That sounds a lot like Berkshire to me.

Over the past seven years Valeant has acquired over 100 businesses. And according to Ackman, they’ve been integrated into the larger organization rather seamlessly. If Pearson is good at one thing, it’s finding efficiency when combining companies.

Why this matters to you

Valeant isn’t slowing down. The company is going to continue buying other firms—large and small—with the goal of increasing its size. That’s how Berkshire works and that’s likely how Valeant is going to continue to work over the coming years.

This matters to you because platform companies are perpetually undervalued. Ackman has two examples to back this up. When the company bought Bausch & Lomb, the stock was valued at $74. The announcement of its agreement to buy made the price jump to $95. When it agreed to buy Salix Pharmaceuticals, the stock jumped from $217 to $250.

Now, there’s no denying that this stock has been on a meteoric rise. And Ackman’s belief is that the company will continue to make acquisitions in the $7-20 billion range every year. Pearson is not looking to create just another company; he wants to build a behemoth. And his strategy is to follow in the footsteps of the greatest investor of all time: Warren Buffett.

All of this, however, doesn’t immediately warrant a buy. Valeant is risky. It has a lot of debt and it doesn’t pay a penny in dividends to investors. Therefore, what you’re hoping for is a continuous rise in the price per share. In the event that the market corrects, this stock will drop because all stocks will drop.

But long term, if Pearson is successful and if Ackman can correctly predict the undervaluation of platform companies, then this stock will reward investors handsomely.

This article represents the opinion of the writer, who may disagree with the “official” recommendation position of a Motley Fool premium service or advisor. We’re Motley! Questioning an investing thesis — even one of our own — helps us all think critically about investing and make decisions that help us become smarter, happier, and richer, so we sometimes publish articles that may not be in line with recommendations, rankings or other content.

Fool contributor Jacob Donnelly has no position in any stocks mentioned. Tom Gardner owns shares of Valeant Pharmaceuticals. The Motley Fool owns shares of Valeant Pharmaceuticals.

More on Investing

rail train
Stocks for Beginners

CP Stock: 1 Key Catalyst Investors Should Watch

After a positive surprise in the last quarter, CP stock (TSX:CP) recently made a change that should have investors excited…

Read more »

Payday ringed on a calendar
Dividend Stocks

Cash Kings: 3 TSX Stocks That Pay Monthly

These stocks are rewarding shareholders with regular monthly dividends and high yields, making them compelling investments for monthly cash.

Read more »

grow dividends
Tech Stocks

Celestica Stock Is up 62% in 2024 Alone, and an Earnings Pop Could Bring Even More

Celestica (TSX:CLS) stock is up an incredible 280% in the last year. But more could be coming when the stock…

Read more »

Airport and plane
Stocks for Beginners

Is Air Canada Stock a Good Buy in April 2024?

Despite rallying by over 20% in the last six months, Air Canada stock could be a great buy for the…

Read more »

Businessman holding AI cloud
Tech Stocks

Stealth AI: 1 Unexpected Stock to Win With Artificial Intelligence

Thomson Reuters (TSX:TRI) stock isn't widely-known for its generative AI prowess, but don't count it out quite yet.

Read more »

Shopping and e-commerce
Tech Stocks

Missed Out on Nvidia? My Best AI Stock to Buy and Hold

Nvidia (NASDAQ:NVDA) stock isn't the only wonderful growth stock to hold for the next 10 years and beyond.

Read more »

Human Hand Placing A Coin On Increasing Coin Stacks In Front Of House
Dividend Stocks

Up 13%, Killam REIT Looks Like It Has More Room to Run

Killam REIT (TSX:KMP.UN) has seen shares climb 13% since market bottom, but come down recently after 2023 earnings.

Read more »

crypto, chart, stocks
Energy Stocks

If You Had Invested $10,000 in Enbridge Stock in 2018, This Is How Much You Would Have Today

Enbridge's big dividend yield isn't free money. Here's why.

Read more »